My site

LAUSANNE, Switzerland-Monday 22 November 2021 [ AETOS Wire ]

(BUSINESS WIRE)-- Philip Morris International Inc. (PMI) (NYSE: PM) has been included for the second consecutive year in the Dow Jones Sustainability Index (DJSI) North America. The index recognizes the top 20 percent of sustainability performers among the 600 largest U.S. and Canadian companies in the S&P Global Broad Market Index—those that exhibit best-in-class performance against environmental, social, and governance (ESG) metrics, as assessed by S&P Global.

Underpinning PMI’s inclusion in the index, the company scored 84 (out of 100) in the 2021 S&P Global Corporate Sustainability Assessment, reflecting an improvement of 10 points over the prior year and a top decile position in the tobacco industry.1 Importantly, PMI led the tobacco industry in 10 of the 24 criteria assessed1, including Innovation Management, which evaluates companies’ research and development spending, p ... Read more »

Delivers reliable broadband services through new India gateway 

MCLEAN, Va-Monday 22 November 2021 [ AETOS Wire ]

(BUSINESS WIRE)-- Intelsat, operator of the world's largest integrated satellite and terrestrial network, announces the expansion of its global FlexMaritime service, now enabling connectivity for vessels traveling in Indian territorial waters and immediately enhancing the service coverage for all of Intelsat’s 8,000 existing FlexMaritime vessels. The landmark development also provides access for Indian-registered vessels to Intelsat’s award-winning global high-throughput maritime network. Intelsat's ... Read more »

• Sanifit Therapeutics and Inositec AG, both clinical stage biopharmaceutical companies, are developing first-in-class treatments for progressive vascular calcification and soft tissue disorders

• Sanifit’s SNF472 is a novel, first-in-class inhibitor of vascular calcification in phase-III, developed for the treatment of calcific uremic arteriolopathy (CUA) and Peripheral Artery Disease (PAD) in patients with end-stage kidney disease

• Inositec’s INS-3001 is being developed in non-dialysis vascular and cardiovascular calcification disorders, such as CKD-associated PAD and Aortic Valve Stenosis (AVS)

• With INS-3001 and SNF472, Vifor Pharma will further strengthen its nephrology portfolio helping patients suffering from accelerated vascular calcification disorders at all stages of chronic kidney disease (CKD)

• Sanifit purchase price includes an upfront payment of EUR 205 million, precommercial milestones for up to E ... Read more »